Abstract
Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Current Drug Targets
Title: Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
Volume: 9 Issue: 9
Author(s): L. Amaral, M. Martins, M. Viveiros, J. Molnar and J. E. Kristiansen
Affiliation:
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Abstract: Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Export Options
About this article
Cite this article as:
Amaral L., Martins M., Viveiros M., Molnar J. and Kristiansen E. J., Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps, Current Drug Targets 2008; 9 (9) . https://dx.doi.org/10.2174/138945008785747798
DOI https://dx.doi.org/10.2174/138945008785747798 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Anti-Infective Agents Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery
Current Drug Discovery Technologies Experimental and Clinical Studies on Rifacinna® - The New Effective Antituberculous Drug (Review)
Recent Patents on Anti-Infective Drug Discovery Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry 3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis
Current Computer-Aided Drug Design 4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Understanding Mass Spectrometry-based Global Mycobacterial Lipidomics
Current Molecular Medicine Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Preface:
Anti-Infective Agents Synthesis and In Vitro Antimicrobial Evaluation of 4-alkyl/aryl-1-(3-phenoxypropionyl)-thiosemicarbazides
Letters in Drug Design & Discovery Dihydroartemisinin and its Analogs: A New Class of Antitubercular Agents
Current Topics in Medicinal Chemistry Cyclospora Cayetanensis: A Review, Focusing on What Some of the Remaining Questions about Cyclosporiasis
Infectious Disorders - Drug Targets Metabolite Concentration as a Criterion for Antibacterial Discovery
Current Computer-Aided Drug Design Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Synthesis, ADME Evaluation, and In Vitro Antimycobacterial Studies of a Novel Series of 2-Thiazolylimino-5-Arylidene-4-Thiazolidinone Derivatives
Anti-Infective Agents Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Novel 2-(2-Benzylidenehydrazinyl)Benzo[d]Thiazole as Potential Antitubercular Agents
Combinatorial Chemistry & High Throughput Screening